Skip to main content
Caplight Logo









AltPep

AltPep

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://altpep.com/

Last Round

Series B

Jun 22, 2023

Total Funding Raised

$120.45M

Company Overview

AltPep is a biotechnology company that operates a proprietary peptide-based platform designed to diagnose and neutralize toxic precursors to amyloid diseases, offering innovative solutions for early detection and treatment.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

Alzheimer's diseasepeptide therapeuticsneurodegenerative diseaseamyloid-betabiotechdrug discoveryearly-stage detectionamyloid oligomerspreclinical developmentdiagnostic assayneuroscienceclinical trialsprotein misfoldingbiopharmatherapeutic pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AltPep Comparables

Compare AltPep with similar companies based on industry and business-model similarity.

AltPep comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Cenna Biosciences, Inc.
79%
Alzinova
79%
Vaxxinity, Inc.
78%

AltPep Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJun 22, 2023
Series BJul 26, 2022
Series AJan 14, 2021

Key People

Founding team and executive leadership

Valerie Daggett

Founder And CEO

Founding Team

Nancy Hill

Chief Product Officer

Executive Team

AltPep Investors

Notable investors and investment history

AltPep investors
InvestorRounds
S32Series B
Senator Investment GroupSeries B
Alexandria Venture InvestmentsSeries B, Series A
Matrix Capital ManagementSeries B, Series A
Partners InvestmentSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 1, 2025

    New preclinical data for SOBIN-AD showed improved behavior in disease models.

  • Dec 1, 2025

    Presented at the CTAD 2025 conference on December 1, 2025.

AltPep Filings

Explore SEC and related filing metadata, where available.

AltPep filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about AltPep's valuation, stock price, and market status.

Is AltPep a public or private company?

AltPep is a private company.

What is the current stock price of AltPep?

AltPep is a private company with no public stock price. No recent secondary market data is available.

How much is AltPep worth (valuation)?

Valuation information for AltPep is not publicly available.

Can I buy AltPep stock?

AltPep shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was AltPep's last funding round?

AltPep's most recent funding round was Series B on June 22, 2023.

Who are the main investors in AltPep?

Key investors in AltPep include Senator Investment Group, Matrix Capital Management.

Will AltPep IPO soon?

No public IPO plans have been announced for AltPep.

How can I track AltPep secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor AltPep's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range30
Year Founded2018
Last FundingJun 22, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?